INIS (Radnostix) ROE % Adjusted to Book Value: -10.32% (As of Mar. 2026)

What is Radnostix ROE % Adjusted to Book Value?

Radnostix INIS +2.73% ROE % Adjusted to Book Value is -10.32% as of Mar. 2026. The stock has 3 warning signs investors should review.

Radnostix's ROE % for the quarter that ended in Mar. 2026 was -170.12%. Radnostix's PB Ratio for the quarter that ended in Mar. 2026 was 16.48. Radnostix's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -10.32%.

Radnostix ROE % Adjusted to Book Value Related Terms

Radnostix ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Radnostix's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radnostix ROE % Adjusted to Book Value Chart

Radnostix Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-2.90

2.11

-4.15

0.05

-2.58

Radnostix Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-1.60	-1.55	-2.69	-5.06	-10.32

INIS vs TLPH, IXHL, ZYBT: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Radnostix's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radnostix ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Radnostix's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Radnostix's ROE % Adjusted to Book Value falls into.

Save Embed

Radnostix ROE % Adjusted to Book Value Calculation

Radnostix's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-22.59%	/	8.75
	=	-2.58%

Radnostix's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-170.12%	/	16.48
	=	-10.32%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of -10.32% mean?

Radnostix (INIS) has a ROE % Adjusted to Book Value of -10.32% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Radnostix and its competitors.

Is Radnostix's ROE % Adjusted to Book Value too high?

Radnostix's current ROE % Adjusted to Book Value is -10.32%.

How does Radnostix's ROE % Adjusted to Book Value compare to TLPH and IXHL?

Radnostix's ROE % Adjusted to Book Value of -10.32% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?

A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Radnostix and its competitors. Radnostix's current ROE % Adjusted to Book Value is -10.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Radnostix stock overvalued right now?

Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 43.8% above its estimated fair value. The current ROE % Adjusted to Book Value is -10.32%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For Radnostix (INIS), the current ROE % Adjusted to Book Value is -10.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radnostix Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TLPH IXHL ZYBT ETST BTAI HYEX SCYX CPHI MRMD RMTI XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Address 4137 Commerce Circle, Idaho Falls, ID, USA, 83401

Website http://www.radnostix.com

Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.